Michael Shetzline - 28 Feb 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
CMO,SVP,Head-Res&Drug
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
28 Feb 2022
Net transactions value
-$189,627
Form type
4
Filing time
02 Mar 2022, 15:01:08 UTC
Previous filing
21 Jan 2022
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $14,723 -1,367 -0.64% $10.77 211,620 28 Feb 2022 Direct F1
transaction IRWD Class A Common Stock Sale $31,351 -2,911 -1.4% $10.77 208,709 28 Feb 2022 Direct F2
transaction IRWD Class A Common Stock Sale $55,584 -5,161 -2.5% $10.77 203,548 28 Feb 2022 Direct F3
transaction IRWD Class A Common Stock Sale $40,969 -3,804 -1.9% $10.77 199,744 28 Feb 2022 Direct F4
transaction IRWD Class A Common Stock Sale $47,000 -4,364 -2.2% $10.77 195,380 28 Feb 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2019.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on April 24, 2020
F5 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.